The average 12 month price objective among brokerages that have updated their coverage on the stock in the past year is $62.54. Other research analysts have also issued reports about the company. (NASDAQ:ACAD). …
Acadia Pharmaceuticals
Institutional investors own 96.80% of the company’s stock. ACADIA …
ACADIA Pharmaceuticals
They now have a Dollars 60 price target on the stock. (NASDAQ:ACAD) a rating of 1.75 on a scale of 1 to 5. ACADIA Pharmaceuticals Inc. has an EPS ratio of -2.15. They now have a United States dollars 29 price …
ACADIA Pharmaceuticals Inc
This is a proprietary realized volatility rating created by Capital Market Laboratories (CMLviz) based on a large number of data interactions for ACADIA Pharmaceuticals Inc (NASDAQ:ACAD) . We examine the little used …
ACADIA Pharmaceuticals Inc
Shares of Acadia Pharmaceuticals Inc. (NASDAQ: ACAD) , a biopharmaceutical company focused on treating ... patient base by …
Acadia Pharmaceuticals
Starting with ACAD, the shares have recently pulled back near their 40-day moving average. According to data from Schaeffer's Senior Quantitative …
Trump Headwinds
(NASDAQ:ACAD) remained flat at $31.77 during trading on Monday ... They now have a Dollars 42 price target on the stock. Finally, Roth Capital reissued a "neutral" rating and issued a $25.00 price objective on shares of …
ACADIA Pharmaceuticals Inc
At the time of publication, Michael Brush held shares of ACAD, INCY …
biotech buyout